Access Safety and Efficacy Post Endovascular Intervention (ASPEN)

Arstasis

Status

Unknown

Conditions

Cardiovascular Disease.

Treatments

Device: Arstasis Access System (AXERA)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01773148

RC-03773

Details and patient eligibility

About

The goal of this study is to assess the safety and effectiveness of the AXERA Access System in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or 6F introducer sheath.

Enrollment

240 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is 18 years of age or older.
Subject is clinically indicated for a PCI or PVI involving access through a 5F or 6F introducer sheath in the femoral artery.
Subject is able to ambulate without assistance prior to the procedure and can be expected to ambulate (20 feet) within 2 hours post procedure.
Female subjects of child bearing potential must have a negative pregnancy test.

Exclusion criteria

Subjects who are pregnant or lactating.
Subject has a pre-existing severe non-cardiac systemic disease/illness or another reason that results in a projected life expectancy of less than 1 year.
Subject has an active systemic or cutaneous infection or inflammation (e.g., septicemia at the time of the procedure).
Subject has systemic hypertension unresponsive to treatment (>180mmHg systolic and >110mm diastolic).
Subject has significant bleeding coagulopathy or platelet disorder, (INR> 2.0), including known thrombocytopenia (platelet count <100,000/µL), thrombasthenia, Von Willebrand's disease, Factor V deficiency, or anemia (hemoglobin <10 g/dL, or hematocrit <30%).
Subject presents with chronic renal insufficiency (creatinine ≥3.0mg/dl).
Subject presents with hemodynamic instability or is in need of emergent surgery or emergent procedure.
Subject presents with ST elevation myocardial infarction.
Subject presents with unstable angina or non-ST elevation myocardial infarction and has troponin level > 3 X upper limit of normal. There must be at least one troponin level drawn > 6 hours after onset of chest pain.
Subject has received low molecular weight heparin < 8 hours before vascular access, glycoprotein IIb/IIIa inhibitor < 24 hours before vascular access, unfractionated heparin by infusion < 1 hour before vascular access, or parenteral heparin at anticoagulant dose (as opposed to DVT prophylaxis)< 6 hours before vascular access.
Subjects who are clinically obese, defined as BMI >40.
Subject has received femoral artery Vessel Closure Implant (VCI) (suture or staple) at the target access site.
Subject has received femoral artery VCI (collagen/PEG/PGA) at the target access site within 90 days of AXERA procedure.
Subject is unable to routinely walk at least 20 feet without assistance (e.g., requires a walker or wheelchair to mobilize, is leg amputee or has known paralysis) or unable to ambulate within 2 hours post procedure.
Subject has had prior vascular surgery or vascular grafts at the target femoral artery access site.
Subject has had a previous target femoral artery complication from angiography (such as pseudoaneurysm, Arteriovenous (AV) fistula, dissection), small CFA, abnormal, absent or weak distal ipsilateral pulse, or presenting with clinically significant peripheral vascular disease in the vicinity of the puncture.
Subject has a high puncture (i.e. above the inferior reflection of the inferior epigastric artery).
Subject has antegrade puncture.
Subject has a stent in the ipsilateral common femoral artery.
Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.